Cite
HARVARD Citation
Aparicio, J. et al. (n.d.). P-191Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Annals of oncology. p. . [Online].